Hematologic Oncology | Specialty

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel

July 3rd 2023

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel

July 3rd 2023

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Ibrutinib-Rituximab and Venetoclax (IRV) Followed by Risk-Stratified R-HyperCVAD/MTX in Young Patients With Untreated Mantle Cell Lymphoma – Phase-II WINDOW-2 Trial

June 30th 2023

Patient Scenario 1: Diagnosis and Risk Stratification of MF

June 30th 2023

After reviewing the first patient scenario of myelofibrosis, experts from the John Theurer Cancer Center reflect on best practices in diagnosing and risk stratifying patients.

Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023

June 29th 2023

Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.

Development of FHD-286 Monotherapy Will Not Continue in Metastatic Uveal Melanoma

June 29th 2023

Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial, further development in this indication will not be pursued.

Emerging Therapies for Treatment of MDS

June 29th 2023

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

June 29th 2023

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Safety and Efficacy of Luspatercept in Frontline Setting in Patients with MDS

June 29th 2023

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Dr Meric-Bernstam on the Investigation of CBX-12 in Advanced or Metastatic Solid Tumors

June 28th 2023

Funda Meric-Bernstam, MD, discusses a first-in-human phase 1/2 study of CBX-12 in patients with advanced or metastatic solid tumors.

Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia From a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib

June 28th 2023

Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

FDA Awards Orphan Drug Designation to KT-253 in AML

June 28th 2023

The FDA has granted an orphan drug designation to the novel, highly potent, and selective MDM2 degrader KT-253 for the treatment of patients with acute myeloid leukemia.

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

June 28th 2023

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Epcoritamab Elicits an ORR of 82% in Relapsed/Refractory Follicular Lymphoma

June 28th 2023

Epcoritamab elicited a confirmed overall response rate of 82% by independent review committee assessment in patients with relapsed or refractory follicular lymphoma who received 2 or more prior systemic treatments, which exceeded the prespecified threshold for efficacy in the phase 1/2 EPCORE NHL-1 trial.

Novel CD19xCD3 Bispecific Antibody May Expand Second-Line Options in Follicular Lymphoma

June 28th 2023

Ryan Jacobs, MD, expands on the initial efficacy and safety data seen with TNB-486, the need for more data on treatment-related CRS to improve toxicity management, and next steps planned for the investigation of this and other bispecific antibodies in relapsed/refractory follicular lymphoma.

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27th 2023

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

Dr Gill on the Efficacy and Genomic Features of Ropeginterferon Alfa-2B in Myelofibrosis

June 27th 2023

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Quizartinib Plus Chemotherapy Improves EFS, RFS in Newly Diagnosed FLT3-ITD–Negative AML

June 27th 2023

Pau Montesinos, MD, PhD, discusses the preliminary results of the QUIWI trial, expands on the potential implications for the use of quizartinib plus chemotherapy in newly diagnosed patients with FLT3-ITD–negative acute myeloid leukemia, and details the next steps for this study and future research.

Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus Obinutuzumab in R/R Follicular Lymphoma

June 27th 2023

The addition of zanubrutinib to obinutuzumab produced superior clinical activity, prolonged survival, and had a favorable toxicity profile compared with obinutuzumab alone in heavily pretreated patients with relapsed/refractory follicular lymphoma.